Despite thousands of pending lawsuits, a harmful blood- thinning drug called Xarelto remains on the market. The FDA issued warnings but even the warnings do not emphasize the futility of the situation once you’ve taken Xarelto. If you or a loved one was taken Xarelto to treat blood clots, you risk the danger of eternal bleeding. Scarily, the life-threatening side effects of Xarelto are exactly the problems the drug is intended to help.
- Uncontrollable bleeding
- High incidence of blood clots
- Increased incidence of stroke
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Death resulting from complications
Xarelto has been prescribed more than 36 million times in the US, according to Xarelto itself, and it remains the most prescribed blood thinner drug in its class. Its danger comes from its entrance into the cardiovascular system. Its aim is to prevent blood clots in patients recovering from joint replacement surgery or coping with atrial fibrillation or deep vein thrombosis. The company has only acknowledged the Xarelto cases with warnings, but not the severe preventative measures and DETAILED warnings it should.
The main theme emphasized in Xarelto lawsuit cases is that Janssen Pharmaceutical Inc. (ultimately owned by Big BIG Pharms Bayer and Johnson and Johnson) needed to thoroughly communicate the severity of all possible risks and side effects. As of November 2018, they provide insufficient information on risks to their millions of prescribers. Whether they purposely downplayed the risks or negligently failed to inform their customers is beside the question because they have had YEARS of lawsuits flying at them at which they could have addressed this terrifying concern.
In December 2014, a federal court even consolidated nearly two-dozen Xarelto lawsuits into a single multi-district litigation. In 2016, four cases were chosen to be evaluated in four bellwether trials. The first three of these trials took place in 2017 and sadly, they were ALL won by Xarelto’s manufacturers. The fourth bellwether trial is pending as of October 2018.
Even when Xarelto was approved in 2011, concerns were raised because the clinical trial emphasized comparing Xarelto to another blood-clot drug, Coumadin. This means that it didn’t emphasize Xarelto causing strokes and bleeding problems as much as it focused on how Xarelto caused fewer problems than Coumadin. The results of the three-year clinical trial involving over 14,000 patients had information glossed over to ensure the drug got approved. Comparing one type of poison to another is a mute case. ALL the facts need to be communicated about Xarelto.
Our firm is currently reviewing Xarelto claims, and we’d be happy to provide a free consultation! To schedule an appointment to discuss your experience with Xarelto, email or call us at (727) 579-4500.